Browsing: eli lilly
Moderna and Merck said Wednesday their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting…
Here’s the funny thing about breast cancer. Actually Reconstructing Charlie—which premiered as one of three short films comprising the Vital…
Weight-loss drugs are becoming a popular employee perk, with almost a third of workers saying they’d switch jobs to get…
On Thursday morning in New York City, Dr. Shiv Rao stood before a room of health system executives and made…
In this week’s edition of InnovationRx, we look at the spreading Ebola epidemic, the Midas list health investors, Lilly’s trio…
Investor optimism about the pill version of weight-loss injectables being developed by Sam Chun Dang Pharm (SCD) in South Korea…
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend in the…
Gallup released a survey this week showing that the obesity rate among US adults has fallen to 37% this year, a significant…
It’s tough to say for sure which growth stocks will be winners without a crystal ball. But investors may wish…
Eli Lilly’s decision to sell its obesity drug Zepbound directly to patients for $499 per month—well below the $2,000 list…